Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease

Journal of Clinical Lipidology

Volumn 8, Issue 5, 2014, Pages 494-500

  Zhang, Yan ^a   Zhu, Cheng Gang ^a   Xu, Rui Xia ^a   Li, Sha ^a   Guo, Yuan Lin ^a   Sun, Jing ^a   Li, Jian Jun ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

C reactive protein; Coronary artery disease; Fibrinogen; Inflammation; PCSK9

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SUBTILISIN; UNCLASSIFIED DRUG; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL LABORATORY; CORONARY ARTERY DISEASE; CORRELATIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; BLOOD; ENZYMOLOGY; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS;

CORONARY ARTERY DISEASE; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPROTEIN CONVERTASES; REGRESSION ANALYSIS; SERINE ENDOPEPTIDASES;

EID: 84908456695     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2014.07.001     Document Type: Article

References (32)

1. Li JJ, Wang HR, Huang CX, Xue JL, Li GS. Enhanced response of blood monocytes to C-reactive protein in patients with unstable angina. Clin Chim Acta. 2005;352:127-133.
2. Klingenberg R, Luscher TF. Inflammation in coronary artery disease and acute myocardial infarction - is the stage set for novel therapies? Curr Pharm Des. 2012;18:4358-4369.
3. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477-1482.
4. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
5. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310-1320.
6. Green D, Foiles N, Chan C, Schreiner PJ, Liu K. Elevated fibrinogen levels and subsequent subclinical atherosclerosis: The cardia study. Atherosclerosis. 2009;202:623-631.
7. Páramo JA, Beloqui O, Roncal C, Benito A, Orbe J. Validation of plasma fibrinogen as a marker of carotid atherosclerosis in subjects free of clinical cardiovascular disease. Haematologica. 2004;89:1226-1231.
8. De Luca G, Verdoia M, Cassetti E, Schaffer A, Cavallino C, Bolzani V, et al. Novara Atherosclerosis Study Group (NAS). High fibrinogen level is an independent predictor of presence and extent of coronary artery disease among italian population. J Thromb Thrombolysis. 2011;31:458-463.
9. Ndrepepa G, Braun S, King L, Fusaro M, Keta D, Cassese S, et al. Relation of fibrinogen level with cardiovascular events in patients with coronary artery disease. Am J Cardiol. 2013;111:804-810.
10. Fibrinogen Studies Collaboration, Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294:1799-1809.
11. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest. 2006;116:2995-3005.
12. Urban D, Pöss J, Böhm M, Laufs U. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol. 2013;62:1401-1408.
13. Cui Q, Ju X, Yang T, Zhang M, Tang W, Chen Q, et al. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis. 2010;213:632-636.
14. Le Bras M, Roquilly A, Deckert V, Langhi C, Feuillet F, Sébille V, et al. Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury. J Clin Endocrinol Metab. 2013;98:E732-E736.
15. Feingold KR, Moser AH, Shigenaga JK, Patzek SM, Grunfeld C. Inflammation stimulates the expression of PCSK9. Biochem Biophys Res Commun. 2008;374:341-344.
16. Tang Z, Jiang L, Peng J, Ren Z, Wei D, Wu C, et al. PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages. Int J Mol Med. 2012;30:931-938.
17. Li S, Guo YL, Xu RX, Zhang Y, Zhu CG, Sun J, et al. Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. Atherosclerosis. 2014;234:441-445.
18. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol. 1957;17:237-246.
19. Guo YL, Liu J, Xu RX, Zhu CG, Wu NQ, Jiang LX, et al. Short-term impact of low-dose atorvastatin on proprotein convertase subtilisin/kexin type 9. Clin Drug Investig. 2013;33:877-883.
20. Koenig W, Khuseyinova N, Baumert J, Meisinger C. Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg Cohort Study, 1984-1998. Clin Chem. 2008;54:335-342.
21. Schnabel RB, Yin X, Larson MG, Yamamoto JF, Fontes JD, Kathiresan S, et al. Multiple inflammatory biomarkers in relation to cardiovascular events and mortality in the community. Arterioscler Thromb Vasc Biol. 2013;33:1728-1733.
22. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost. 2003;89:601-609.
23. Reinhart WH. Fibrinogen-marker or mediator of vascular disease? Vasc Med. 2003;8:211-216.
24. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-454.
25. Biasucci LM. Cdc/aha workshop on markers of inflammation and cardiovascular disease: Application to clinical and public health practice: Clinical use of inflammatory markers in patients with cardiovascular diseases: A background paper. Circulation. 2004;110:e560-e567.
26. Bickel C, Rupprecht HJ, Blankenberg S, Espiniola-Klein C, Schlitt A, Rippin G, et al. AtheroGene Investigators. Relation of markers of inflammation (c-reactive protein, fibrinogen, von willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol. 2002;89:901-908.
27. Redman CM, Xia H. Fibrinogen biosynthesis. Assembly, intracellular degradation, and association with lipid synthesis and secretion. Ann N Y Acad Sci. 2001;936:480-495.
28. Rankinen T, Hietanen E, Väisänen S, Lehtiö M, Penttilä I, Bouchard C, et al. Relationship between lipid peroxidation and plasma fibrinogen in middle-aged men. Thromb Res. 2000;99:453-459.
29. Stein EA, Swergold GD. Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics. Curr Atheroscler Rep. 2013;15:310.
30. Lee P, Hegele RA. Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia. Expert Opin Investig Drugs. 2013;22:1411-1423.
31. Denis M, Marcinkiewicz J, Zaid A, Gauthier D, Poirier S, Lazure C, et al. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation. 2012;125:894-901.
32. Lowe GD. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost. 2005;3:1618-1627.